{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:13:51Z","timestamp":1781590431084,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["Grant No. 2021-I2M-1-069"],"award-info":[{"award-number":["Grant No. 2021-I2M-1-069"]}]},{"name":"Program for Foreign Talent of Ministry of Science and Technology of the People\u2019s Republic of China","award":["Grant No. G2021194015L"],"award-info":[{"award-number":["Grant No. G2021194015L"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11030-024-10856-2","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T04:19:55Z","timestamp":1717474795000},"page":"337-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Discovery of a novel DYRK1A inhibitor with neuroprotective activity by virtual screening and in vitro biological evaluation"],"prefix":"10.1007","volume":"29","author":[{"given":"Xinxin","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6837-5320","authenticated-orcid":false,"given":"Chenliang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6786-1269","authenticated-orcid":false,"given":"Nianzhuang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-8900","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1014-8918","authenticated-orcid":false,"given":"Xuehui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9567-3763","authenticated-orcid":false,"given":"Jie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"20","key":"10856_CR1","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00018-009-0123-2","volume":"66","author":"J Park","year":"2009","unstructured":"Park J, Song WJ, Chung KC (2009) Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci 66(20):3235\u20133240. https:\/\/doi.org\/10.1007\/s00018-009-0123-2","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10856_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5483\/bmbrep.2009.42.1.006","volume":"42","author":"J Park","year":"2009","unstructured":"Park J, Oh Y, Chung KC (2009) Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. BMB Rep 42(1):6\u201315. https:\/\/doi.org\/10.5483\/bmbrep.2009.42.1.006","journal-title":"BMB Rep"},{"issue":"Pt 15","key":"10856_CR3","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1242\/jcs.00618","volume":"116","author":"M Alvarez","year":"2003","unstructured":"Alvarez M, Estivill X, de la Luna S (2003) DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly. J Cell Sci 116(Pt 15):3099\u20133107. https:\/\/doi.org\/10.1242\/jcs.00618","journal-title":"J Cell Sci"},{"issue":"2","key":"10856_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1096\/fj.10-165837","volume":"25","author":"S Aranda","year":"2011","unstructured":"Aranda S, Laguna A, de la Luna S (2011) DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J 25(2):449\u2013462. https:\/\/doi.org\/10.1096\/fj.10-165837","journal-title":"FASEB J"},{"issue":"4","key":"10856_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1074\/jbc.275.4.2431","volume":"275","author":"S Himpel","year":"2000","unstructured":"Himpel S, Tegge W, Frank R, Leder S, Joost HG, Becker W (2000) Specificity determinants of substrate recognition by the protein kinase DYRK1A. J Biol Chem 275(4):2431\u20132438. https:\/\/doi.org\/10.1074\/jbc.275.4.2431","journal-title":"J Biol Chem"},{"issue":"16","key":"10856_CR6","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.3390\/ijms22169098","volume":"22","author":"S Demuro","year":"2021","unstructured":"Demuro S, Di Martino RMC, Ortega JA, Cavalli A (2021) GSK-3\u03b2, FYN, and DYRK1A: master regulators in neurodegenerative pathways. Int J Mol Sci 22(16):9098. https:\/\/doi.org\/10.3390\/ijms22169098","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10856_CR7","doi-asserted-by":"publisher","first-page":"e05920","DOI":"10.7554\/eLife.05920","volume":"4","author":"B Khor","year":"2015","unstructured":"Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K et al (2015) The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife 4(4):e05920. https:\/\/doi.org\/10.7554\/eLife.05920","journal-title":"Elife"},{"issue":"6","key":"10856_CR8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.celrep.2018.04.008","volume":"23","author":"EJ Rozen","year":"2018","unstructured":"Rozen EJ, Roewenstrunk J, Barallobre MJ, Di Vona C, Jung C, Figueiredo AF et al (2018) DYRK1A kinase positively regulates angiogenic responses in endothelial cells. Cell Rep 23(6):1867\u20131878. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.008","journal-title":"Cell Rep"},{"issue":"10","key":"10856_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/brainsci8100187","volume":"8","author":"A Feki","year":"2018","unstructured":"Feki A, Hibaoui Y (2018) DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome. Brain Sci 8(10):187. https:\/\/doi.org\/10.3390\/brainsci8100187","journal-title":"Brain Sci"},{"issue":"11","key":"10856_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/cn300094k","volume":"3","author":"B Smith","year":"2012","unstructured":"Smith B, Medda F, Gokhale V, Dunckley T, Hulme C (2012) Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer\u2019s? ACS Chem Neurosci 3(11):857\u2013872. https:\/\/doi.org\/10.1021\/cn300094k","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"10856_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","volume":"278","author":"J Wegiel","year":"2011","unstructured":"Wegiel J, Gong CX, Hwang YW (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J 278(2):236\u2013245. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07955.x","journal-title":"FEBS J"},{"issue":"1","key":"10856_CR12","doi-asserted-by":"publisher","first-page":"e970048","DOI":"10.4161\/23723548.2014.970048","volume":"2","author":"P Fern\u00e1ndez-Mart\u00ednez","year":"2015","unstructured":"Fern\u00e1ndez-Mart\u00ednez P, Zahonero C, S\u00e1nchez-G\u00f3mez P (2015) DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol Cell Oncol 2(1):e970048. https:\/\/doi.org\/10.4161\/23723548.2014.970048","journal-title":"Mol Cell Oncol"},{"key":"10856_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12935-018-0574-3","volume":"18","author":"KL Uhl","year":"2018","unstructured":"Uhl KL, Schultz CR, Geerts D, Bachmann AS (2018) Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma. Cancer Cell Int 18:82. https:\/\/doi.org\/10.1186\/s12935-018-0574-3","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10856_CR14","doi-asserted-by":"publisher","first-page":"e132594","DOI":"10.1172\/jci.insight.132594","volume":"5","author":"C Ackeifi","year":"2020","unstructured":"Ackeifi C, Swartz E, Kumar K, Liu H, Chalada S, Karakose E et al (2020) Pharmacologic and genetic approaches define human pancreatic \u03b2 cell mitogenic targets of DYRK1A inhibitors. JCI Insight 5(1):e132594. https:\/\/doi.org\/10.1172\/jci.insight.132594","journal-title":"JCI Insight"},{"key":"10856_CR15","doi-asserted-by":"publisher","unstructured":"Ackeifi C, Wang P, Karakose E, Manning Fox JE, Gonz\u00e1lez BJ, Liu H et al (2020) GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human \u03b2 cell regeneration. Sci Transl Med 12(530):eaaw9996. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9996","DOI":"10.1126\/scitranslmed.aaw9996"},{"issue":"6","key":"10856_CR16","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dbi16-0013","volume":"65","author":"BF Belgardt","year":"2016","unstructured":"Belgardt BF, Lammert E (2016) DYRK1A: a promising drug target for islet transplant-based diabetes therapies. Diabetes 65(6):1496\u20131498. https:\/\/doi.org\/10.2337\/dbi16-0013","journal-title":"Diabetes"},{"issue":"3","key":"10856_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408(3):297\u2013315. https:\/\/doi.org\/10.1042\/bj20070797","journal-title":"Biochem J"},{"issue":"8","key":"10856_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s1474-4422(16)30034-5","volume":"15","author":"R de la Torre","year":"2016","unstructured":"de la Torre R, de Sola S, Hernandez G, Farr\u00e9 M, Pujol J, Rodriguez J et al (2016) Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down\u2019s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(8):801\u2013810. https:\/\/doi.org\/10.1016\/s1474-4422(16)30034-5","journal-title":"Lancet Neurol"},{"issue":"21","key":"10856_CR19","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1111\/j.1742-4658.2009.07346.x","volume":"276","author":"N G\u00f6ckler","year":"2009","unstructured":"G\u00f6ckler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276(21):6324\u20136337. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07346.x","journal-title":"FEBS J"},{"issue":"12","key":"10856_CR20","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1021\/jm200274d","volume":"54","author":"M Debdab","year":"2011","unstructured":"Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P et al (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem 54(12):4172\u20134186. https:\/\/doi.org\/10.1021\/jm200274d","journal-title":"J Med Chem"},{"key":"10856_CR21","doi-asserted-by":"publisher","unstructured":"Nguyen TL, Duchon A, Manousopoulou A, Loa\u00ebc N, Villiers B, Pani G et al (2018) Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A. Dis Model Mech 11(9):dmm035634. https:\/\/doi.org\/10.1242\/dmm.035634","DOI":"10.1242\/dmm.035634"},{"key":"10856_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncomms1090","volume":"1","author":"Y Ogawa","year":"2010","unstructured":"Ogawa Y, Nonaka Y, Goto T, Ohnishi E, Hiramatsu T, Kii I et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun 1:86. https:\/\/doi.org\/10.1038\/ncomms1090","journal-title":"Nat Commun"},{"issue":"1","key":"10856_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.joca.2017.08.015","volume":"26","author":"V Deshmukh","year":"2018","unstructured":"Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L et al (2018) A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26(1):18\u201327. https:\/\/doi.org\/10.1016\/j.joca.2017.08.015","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"10856_CR24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.joca.2019.05.006","volume":"27","author":"V Deshmukh","year":"2019","unstructured":"Deshmukh V, O\u2019Green AL, Bossard C, Seo T, Lamangan L, Ibanez M et al (2019) Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 27(9):1347\u20131360. https:\/\/doi.org\/10.1016\/j.joca.2019.05.006","journal-title":"Osteoarthritis Cartilage"},{"issue":"5","key":"10856_CR25","doi-asserted-by":"publisher","first-page":"e13000","DOI":"10.1111\/acel.13000","volume":"18","author":"B Melchior","year":"2019","unstructured":"Melchior B, Mittapalli GK, Lai C, Duong-Polk K, Stewart J, G\u00fcner B et al (2019) Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: a potential therapeutic for Alzheimer\u2019s disease. Aging Cell 18(5):e13000. https:\/\/doi.org\/10.1111\/acel.13000","journal-title":"Aging Cell"},{"key":"10856_CR26","doi-asserted-by":"publisher","first-page":"154481","DOI":"10.1016\/j.phymed.2022.154481","volume":"107","author":"Y Lin","year":"2022","unstructured":"Lin Y, Zhang Y, Wang D, Yang B, Shen YQ (2022) Computer especially AI-assisted drug virtual screening and design in traditional Chinese medicine. Phytomedicine 107:154481. https:\/\/doi.org\/10.1016\/j.phymed.2022.154481","journal-title":"Phytomedicine"},{"issue":"4","key":"10856_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1573409914666181003153249","volume":"15","author":"V Asati","year":"2019","unstructured":"Asati V, Ghode P, Bajaj S, Jain SK, Bharti SK (2019) 3D-QSAR and molecular docking studies on oxadiazole substituted benzimidazole derivatives: validation of experimental inhibitory potencies towards COX-2. Curr Comput Aided Drug Des 15(4):277\u2013293. https:\/\/doi.org\/10.2174\/1573409914666181003153249","journal-title":"Curr Comput Aided Drug Des"},{"key":"10856_CR28","doi-asserted-by":"publisher","first-page":"115826","DOI":"10.1016\/j.ejmech.2023.115826","volume":"261","author":"S Gupta","year":"2023","unstructured":"Gupta S, Baweja GS, Singh S, Irani M, Singh R, Asati V (2023) Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: design, synthesis and in vivo studies. Eur J Med Chem 261:115826. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115826","journal-title":"Eur J Med Chem"},{"key":"10856_CR29","doi-asserted-by":"publisher","first-page":"135596","DOI":"10.1016\/j.molstruc.2023.135596","volume":"1287","author":"G Shankar","year":"2023","unstructured":"Shankar G, Gurkaran S, Gupta GD, Asati V (2023) Identification of potential N-substituted 5-benzylidenethiazolidine-2,4-dione derivatives as \u03b1-amylase inhibitors: computational cum synthetic studies. J Mol Struct 1287:135596. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135596","journal-title":"J Mol Struct"},{"issue":"23","key":"10856_CR30","doi-asserted-by":"publisher","first-page":"9569","DOI":"10.1021\/jm401049v","volume":"56","author":"S Gourdain","year":"2013","unstructured":"Gourdain S, Dairou J, Denhez C, Bui LC, Rodrigues-Lima F, Janel N et al (2013) Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity. J Med Chem 56(23):9569\u20139585. https:\/\/doi.org\/10.1021\/jm401049v","journal-title":"J Med Chem"},{"issue":"4","key":"10856_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nchembio.530","volume":"7","author":"JT Metz","year":"2011","unstructured":"Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ (2011) Navigating the kinome. Nat Chem Biol 7(4):200\u2013202. https:\/\/doi.org\/10.1038\/nchembio.530","journal-title":"Nat Chem Biol"},{"key":"10856_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jmgm.2017.01.014","volume":"72","author":"T Koyama","year":"2017","unstructured":"Koyama T, Yamaotsu N, Nakagome I, Ozawa SI, Yoshida T, Hayakawa D et al (2017) Multi-step virtual screening to develop selective DYRK1A inhibitors. J Mol Graph Model 72:229\u2013239. https:\/\/doi.org\/10.1016\/j.jmgm.2017.01.014","journal-title":"J Mol Graph Model"},{"issue":"10","key":"10856_CR33","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.1021\/acs.jmedchem.1c00023","volume":"64","author":"C Weber","year":"2021","unstructured":"Weber C, Sipos M, Paczal A, Balint B, Kun V, Foloppe N et al (2021) Structure-guided discovery of potent and selective DYRK1A inhibitors. J Med Chem 64(10):6745\u20136764. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00023","journal-title":"J Med Chem"},{"issue":"8","key":"10856_CR34","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/ci300604z","volume":"53","author":"DR Koes","year":"2013","unstructured":"Koes DR, Baumgartner MP, Camacho CJ (2013) Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model 53(8):1893\u20131904. https:\/\/doi.org\/10.1021\/ci300604z","journal-title":"J Chem Inf Model"},{"issue":"19","key":"10856_CR35","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1021\/jp984217f","volume":"103","author":"WRP Scott","year":"1999","unstructured":"Scott WRP, H\u00fcnenberger PH, Tironi IG, Mark AE, Billeter SR, Fennen J et al (1999) The GROMOS biomolecular simulation program package. J Comput Chem 103(19):3596\u20133607. https:\/\/doi.org\/10.1021\/jp984217f","journal-title":"J Comput Chem"},{"key":"10856_CR36","doi-asserted-by":"publisher","unstructured":"Henderson SH, Sorrell F, Bennett J, Fedorov O, Hanley MT, Godoi PH et al (2021) Discovery and characterization of selective and ligand-efficient DYRK Inhibitors. J Med Chem 4(15):11709\u201311728. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01115","DOI":"10.1021\/acs.jmedchem.1c01115"},{"issue":"5","key":"10856_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","volume":"104","author":"SR Ryoo","year":"2008","unstructured":"Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS et al (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease. J Neurochem 104(5):1333\u20131344. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05075.x","journal-title":"J Neurochem"},{"issue":"16","key":"10856_CR38","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/jcc.20303","volume":"26","author":"M Christen","year":"2005","unstructured":"Christen M, H\u00fcnenberger PH, Bakowies D, Baron R, B\u00fcrgi R, Geerke DP et al (2005) The GROMOS software for biomolecular simulation: GROMOS05. J Comput Chem 26(16):1719\u20131751. https:\/\/doi.org\/10.1002\/jcc.20303","journal-title":"J Comput Chem"},{"issue":"W1","key":"10856_CR39","doi-asserted-by":"publisher","first-page":"W331","DOI":"10.1093\/nar\/gkx312","volume":"45","author":"LS Dodda","year":"2017","unstructured":"Dodda LS, Cabeza de Vaca I, Tirado-Rives J, Jorgensen WL (2017) LigParGen web server: an automatic OPLS-AA parameter generator for organic ligands. Nucleic Acids Res 45(W1):W331\u2013W336. https:\/\/doi.org\/10.1093\/nar\/gkx312","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"10856_CR40","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.3390\/molecules24224090","volume":"24","author":"C Lechner","year":"2019","unstructured":"Lechner C, Fla\u00dfhoff M, Falke H, Preu L, Loa\u00ebc N, Meijer L et al (2019) [b]-Annulated halogen-substituted indoles as potential DYRK1A inhibitors. Molecules 24(22):4090. https:\/\/doi.org\/10.3390\/molecules24224090","journal-title":"Molecules"},{"issue":"10","key":"10856_CR41","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4155\/fmc-2019-0307","volume":"12","author":"N Berdigaliyev","year":"2020","unstructured":"Berdigaliyev N, Aljofan M (2020) An overview of drug discovery and development. Future Med Chem 12(10):939\u2013947. https:\/\/doi.org\/10.4155\/fmc-2019-0307","journal-title":"Future Med Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10856-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10856-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10856-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T16:41:35Z","timestamp":1738341695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10856-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10856"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10856-2","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}